Inflammatory Markers and Risk of Developing Type 2 Diabetes in Women

Diabetes

Volumn 53, Issue 3, 2004, Pages 693-700

  Hu, Frank B ^a,b   Meigs, James B ^c   Li, Tricia Y ^a   Rifai, Nader ^d   Manson, JoAnn E ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ADULT; ARTICLE; BODY MASS; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HIGH RISK POPULATION; HUMAN; INFLAMMATION; LIFESTYLE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; RISK ASSESSMENT; RISK FACTOR;

ADULT; ANTIGENS, CD; BIOLOGICAL MARKERS; BODY CONSTITUTION; BODY MASS INDEX; C-REACTIVE PROTEIN; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INFLAMMATION; INSULIN; INTERLEUKIN-6; MENOPAUSE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RISK FACTORS; SMOKING; UNITED STATES;

EID: 1442301080     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.53.3.693     Document Type: Article

References (52)

1. Wilding JPH: Obesity and nutritional factors in the pathogenesis of type 2 diabetes mellitus. In Textbook of Diabetes. 3rd ed. Pickup JC, Ed. Oxford, U.K., Blackwell Science Ltd., 2003, p. 21.21-21.16
2. Das UN: Is obesity an inflammatory condition? Nutrition 17:953-966, 2001
3. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW: C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19:972-978, 1999
4. Hu FB, Stampfer MJ: Is type 2 diabetes mellitus a vascular condition? Arterioscler Thromb Vasc Biol 23:1715-1716, 2003
5. Hotamisligil GS, Spiegelman BM: Tumor necrosis factor-α: a key component of the obesity-diabetes link. Diabetes 43:1271-1278, 1994
6. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM: Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95:2409-2415, 1995
7. Caballero AE, Arora S, Saouaf R, Lim SC, Smakowski P, Park JY, King GL, LoGerfo FW, Horton ES, Veves A: Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 48:1856-1862, 1999
8. Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation N Engl J Med 340:448-454, 1999. [published erratum appears in N Engl J Med 29:1376, 1999]
9. Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation N Engl J Med 340:448-454, 1999. [published erratum appears in N Engl J Med 29:1376, 1999]
10. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327-334, 2001
11. Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, Tracy RP: The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 50:2384-2389, 2001
12. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, O'Reilly DS, Packard CJ, Sattar N: C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51:1596-1600, 2002
13. Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF: Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52:812-817, 2003
14. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM: Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 25:2016-2021, 2002
15. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM: Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 51:1131-1137, 2002
16. Thorand B, Lowel H, Schneider A, Kolb H, Meisinger C, Frohlich M, Koenig W: C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. Arch Intern Med 163:93-99, 2003
17. Krakoff J, Funahashi T, Stehouwer CD, Schalkwijk CG, Tanaka S, Matsuzawa Y, Kobes S, Tataranni PA, Hanson RL, Knowler WC, Lindsay RS: Inflammatory markers, Adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 26:1745-1751, 2003
18. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039-1057, 1979
19. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183-1194, 1997
20. Manson JE, Colditz, GA, Stampfer MJ, Willett WC, Krolewski AS, Rosner B, Arky RA, Speizer FE, Hennekens CH: A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 151:1141-1147, 1991
21. Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH, Rimm E, Colditz GA: Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 161:1581-1586, 2001
22. Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, Hennekens CH, Speizer FE: Body weight and mortality among women. N Engl J Med 333:677-685, 1995
23. Carey VJ, Walters EE, Colditz; GA, Solomon CG, Willett WC, Rosner BA, Speizer FE, Manson JE: Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women: the Nurses' Health Study. Am J Epidemiol 145:614-619, 1997
24. Hu FB, Sigal RJ, Rich-Edwards JW, Colditz GA, Solomon CG, Willett WC, Speizer FE, Manson JE: Walking compared with vigorous physical activity and risk of type 2 diabetes in women: a prospective study. JAMA 282:1433-1439, 1999
25. Willett WC, Sampson L, Stampfer MJ, Rosner B, Bain C, Witschi J, Hennekens CH, Speizer FE: Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol 122:51-65, 1985
26. Hu FB, Manson JE, Stampfer MJ, Colditz; G, Liu S, Solomon CG, Willett WC: Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 345:790-797, 2001
27. Hankinson SE, London SJ, Chute CG, Barbieri RL, Jones L, Kaplan LA, Sacks FM, Stampfer MJ: Effect of transport conditions on the stability of biochemical markers in blood. Clin Chem 35:2313-2316, 1989
28. SAS Institute Inc: SAS/STAT User's Guide. V. 6, 4th ed., vol. 1. Cary, NC, SAS Institute Inc., 1989
29. Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, Hoogeveen R, Folsom AR, Heiss G: Low-grade systemic inflammation and the development of type 2 diabetes: the Atherosclerosis Risk in Communities Study. Diabetes 52:1799-1805, 2003
30. Meigs JB, Hu FB, Manson JE: Endothelial dysfunction predicts development of type 2 diabetes (Abstract). Diabetes 52 (Suppl. 1):A58, 2003
31. Ridker PM: Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107:363-369, 2003
32. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB: Elevated C-reactive protein levels in overweight and obese adults. JAMA 282:2131-2135, 1999
33. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102:42-47, 2000
34. Pradhan AD, Cook NR, Buring JE, Manson JE, Ridker PM: C-reactive protein is independently associated with fasting insulin in nondiabetic women. Arterioscler Thromb Vasc Biol 23:650-655, 2003
35. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837-853, 1998
36. Pradhan AD, Ridker PM: Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J 23:831-834, 2002
37. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973-979, 1997
38. Pickup JC, Mattock MB, Chusney GD, Burt D: NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40:1286-1292, 1997
39. Pickup JC, Crook MA: Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41:1241-1248, 1998
40. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87-91, 1993
41. Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA: The expression of TNF alpha by human muscle: relationship to insulin resistance. J Clin Invest 97:1111-1116, 1996
42. Chu NF, Spiegelman D, Rifai N, Hotamisligil GS, Rimm EB: Glycemic status and soluble tumor necrosis factor receptor levels in relation to plasma leptin concentrations among normal weight and overweight US men. Int J Obes Relat Metab Disord 24:1085-1092, 2000
43. Chu NF, Spiegelman D, Hotamisligil GS, Rifai N, Stampfer M, Rimm EB: Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease risk factors among men. Atherosclerosis 157:495-503, 2001
44. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, Giugliano D: Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 289:1799-1804, 2003
45. Manns PJ, Williams DP, Snow CM, Wander RC: Physical activity, body fat, and serum C-reactive protein in postmenopausal women with and without hormone replacement. Am J Human Biol 15:91-100, 2003
46. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001
47. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
48. Tan KC, Chow WS, Tam SC, Ai VH, Lam CH, Lam KS: Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab 87:563-568, 2002
49. O'Driscoll G, Green D, Maiorana A, Stanton K, Colreavy F, Taylor R: Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 33:1506-1511, 1999
50. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A: Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103:357-362, 2001
51. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, Zimman B: Ramipril and the development of diabetes. JAMA 286:1882-1885, 2001
52. Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif JC: Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 107:1291-1296, 2003